New injection shows promise for kidney disease in early trial

NCT ID NCT07289763

Recruiting now Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests an experimental drug called SHR-2173 in 75 adults with primary membranous nephropathy, a kidney condition that can lead to kidney failure. The drug is given as an injection over several doses. Researchers are checking if it is safe and can help control the disease by reducing protein in the urine and improving kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-2173 injection
What this could lead to: If successful, this could lead to a new treatment option that helps control primary membranous nephropathy and reduce kidney damage.
What could go wrong: This is an early Phase 2 trial with only 75 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

General hospital of eastern theater command
RECRUITING

Nanjing, Jiangsu, 210002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.